Regulatory Applications Accepted in the US and Japan for Bristol Myers Squibb's Breyanzi (Lisocabtagene Maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Bristol-Myers Squibb Company -0.18%

Bristol-Myers Squibb Company




Bristol Myers Squibb (NYSE:BMY) today announced three regulatory acceptances from the U.S. Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare (MHLW) for Breyanzi® (lisocabtagene maraleucel). In the U.S., the FDA has accepted the company's two supplemental Biologics License Applications (sBLA) for Breyanzito expand into new indications to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and relapsed or refractory mantle cell lymphoma (MCL) after a Bruton tyrosine kinase inhibitor (BTKi). The FDA has granted both applications Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 23, 2024 for Breyanzi in relapsed or refractory FL and May 31, 2024 for Breyanzi in relapsed or refractory MCL.

Japan's MHLW has also accepted Bristol Myers Squibb's supplemental New Drug Application (sNDA) for Breyanzi for the treatment of relapsed or refractory FL.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via